Coronavirus Stocks: Pfizer, BioNTech, Mesoblast
Australian biotech Mesoblast (MESO) rocketed 17% on earnings, and on a Covid-19 treatment partnership with Switzerland's Novartis (NVS). Volatile Mesoblast shares have a 60% year-to-date gain, but are down 44% from a late-August high.
This came out tonight on the US Investor business Daily.
Watch this space.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-362
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.04 |
Change
-0.085(7.59%) |
Mkt cap ! $1.224B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.04 | $5.584M | 5.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 103097 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 30011 | 9 |
View Market Depth
| Last trade - 11.02am 09/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |